Advertisement
Advertisement
U.S. Markets open in 8 hrs 53 mins
Advertisement
Advertisement
Advertisement
Advertisement

Alimera Sciences, Inc. (ALIM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.03-0.16 (-3.08%)
At close: 04:00PM EST
Advertisement

Alimera Sciences, Inc.

6120 Windward Parkway
Suite 290
Alpharetta, GA 30005
United States
678 990 5740
http://www.alimerasciences.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees130

Key Executives

NameTitlePayExercisedYear Born
Mr. Charles Daniel MyersNon-Exec. Chairman & Consultant205kN/A1954
Mr. Richard S. Eiswirth Jr.Pres, CEO & Director630.37kN/A1968
Mr. David R. HollandCo-Founder, Chief Marketing Officer and Sr. VP of Corp. Communications & Managed Markets429.36kN/A1964
Dr. Philip AshmanCOO & Sr. VP of Commercial Operations - Europe417.14kN/A1965
Mr. J. Philip JonesChief Financial OfficerN/AN/A1964
Christopher S. VisickVP, Gen. Counsel & Sec.N/AN/AN/A
Dr. David DyerChief Retina SpecialistN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Corporate Governance

Alimera Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement